Android app Apple app link

Senti Bio Shares Catapult After $37.6M Private Placement, Positive Phase 1 Trial

By MarketWatch   |   1 year ago
Senti Bio Shares Catapult After $37.6M Private Placement, Positive Phase 1 Trial

Senti Biosciences experienced a significant surge in its shares due to a successful private placement and promising early results for a blood cancer treatment. The company raised $37.6 million through a private placement and reported positive outcomes in a phase 1 trial for treating certain types of leukemia.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.